Miriam E. Marques

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

GATA4 loss promotes mutant Kras-driven pancreatic ductal adenocarcinoma in the absence of canonical precursor lesions.

GATA4 loss promotes mutant Kras-driven pancreatic ductal adenocarcinoma in the absence of canonical precursor lesions.

Journal: bioRxiv : the preprint server for biology

Published: June 05, 2026

Paratesticular Solitary Fibrous Tumor: A Case Report With Sonographic and Histopathologic Insights.

Paratesticular Solitary Fibrous Tumor: A Case Report With Sonographic and Histopathologic Insights.

Journal: Cureus

Published: May 22, 2026

STAG2 cohesin cooperates with DREAM to maintain quiescence and suppress tumourigenesis in the urothelium.

STAG2 cohesin cooperates with DREAM to maintain quiescence and suppress tumourigenesis in the urothelium.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO study.

Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO study.

Journal: Cell reports. Medicine

Published: February 22, 2025

Predictive signature of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer integrating mRNA expression, taxonomic subtypes, and clinicopathological features.

Predictive signature of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer integrating mRNA expression, taxonomic subtypes, and clinicopathological features.

Journal: Frontiers in oncology

Published: January 31, 2023

Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities.

Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities.

Journal: European urology oncology

Published: August 11, 2022

Tumor and Stromal Cell Targeting with Nintedanib and Alpelisib Overcomes Intrinsic Bladder Cancer Resistance.

Tumor and Stromal Cell Targeting with Nintedanib and Alpelisib Overcomes Intrinsic Bladder Cancer Resistance.

Journal: Molecular cancer therapeutics

Published: August 04, 2021

Resource use during systematic review production varies widely: a scoping review.

Resource use during systematic review production varies widely: a scoping review.

Journal: Journal of clinical epidemiology

Published: March 17, 2021

Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models.

Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models.

Journal: Genome medicine

Published: January 13, 2021

Immunohistochemistry-Based Taxonomical Classification of Bladder Cancer Predicts Response to Neoadjuvant Chemotherapy.

Immunohistochemistry-Based Taxonomical Classification of Bladder Cancer Predicts Response to Neoadjuvant Chemotherapy.

Journal: Cancers

Published: June 05, 2020

Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features.

Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features.

Journal: Cancer research

Published: May 29, 2019

PIcKing on Fibroblast Growth Factor Receptors as Bladder Cancer Therapeutic Targets.

PIcKing on Fibroblast Growth Factor Receptors as Bladder Cancer Therapeutic Targets.

Journal: European urology

Published: January 20, 2017

Showing 1-12 of 21

Last Updated: 09/26/2026